| 000 | 01877 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516222758.0 | ||
| 264 | 0 | _c20140723 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMoa1316158 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCaplin, Martyn E | |
| 245 | 0 | 0 |
_aLanreotide in metastatic enteropancreatic neuroendocrine tumors. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cJul 2014 |
||
| 300 |
_a224-33 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 |
_aDiarrhea _xetiology |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xdrug therapy |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPeptides, Cyclic _xadverse effects |
| 650 | 0 | 4 |
_aSomatostatin _xadverse effects |
| 700 | 1 | _aPavel, Marianne | |
| 700 | 1 | _aĆwikła, Jarosław B | |
| 700 | 1 | _aPhan, Alexandria T | |
| 700 | 1 | _aRaderer, Markus | |
| 700 | 1 | _aSedláčková, Eva | |
| 700 | 1 | _aCadiot, Guillaume | |
| 700 | 1 | _aWolin, Edward M | |
| 700 | 1 | _aCapdevila, Jaume | |
| 700 | 1 | _aWall, Lucy | |
| 700 | 1 | _aRindi, Guido | |
| 700 | 1 | _aLangley, Alison | |
| 700 | 1 | _aMartinez, Séverine | |
| 700 | 1 | _aBlumberg, Joëlle | |
| 700 | 1 | _aRuszniewski, Philippe | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 371 _gno. 3 _gp. 224-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMoa1316158 _zAvailable from publisher's website |
| 999 |
_c23999695 _d23999695 |
||